The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.» Read More
AbbVie reported strong earnings on demand for its Humira drug and said it could deliver strong long-term growth without another big merger bid.
Gilead Sciences reported Tuesday that sales of its Hepatitis C drug, Sovaldi, fell nearly 20 percent from the prior quarter.
A nasty Wall Street divorce has touched two biotech CEOs and appears to have moved their company stocks down over drug use allegations.
Swiss drugmaker Novartis reported better-than-expected results on Tuesday, as strong sales of new products helped offset the expiration of a key patent.
Amgen's CEO provided an answer to Dan Loeb's recent suggestion that the biotechnology company be split up. In short, he said, it doesn't make sense.
Pfizer earnings topped analysts' expectations on Tuesday, helped by demand for its cancer drugs and medicines in emerging markets.
DuPont reported a 52 percent jump in profit as operating margins rose in five of its seven businesses.
Shares of Sanofi tumbled around 7.4 percent early on Tuesday after the French drugmaker reported weaker-than-expected Q3 sales.
Amgen reported better-than expected quarterly results and said it projects full-year earnings and revenue to come in above analysts' forecasts.
Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.
CNBC's Bertha Coombs discusses how biotech stocks have reached new all-time highs since the sector sold off in the spring.
With some 84 million people in the U.S. struggling with obesity, investing in obesity stocks has become a Wall Street trend.
The roller coaster ride for Sarepta continues, as it's likely to file for approval of its muscular dystrophy drug in mid-2015.
Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.
The FDA wants more data on the new drug, reports CNBC's Meg Tirrell with the latest details.
Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.
U.S. drugmaker Pfizer's new $11 billion share repurchase plan is deflating expectations that it will make a new bid for AstraZeneca.
The patient, who was taking Tecfidera, died earlier this month.
GlaxoSmithKline (GSK) reported third-quarter revenue lower than analysts forecast, as sales of blockbuster asthma drug Advair continued to fall.
An experimental trial Ebola vaccine could be in use in West Africa as early as January, the WHO said. NBC News reports.
Get the best of CNBC in your inbox